Drugs / IBIO123
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT05303376 | Feb 2022 → Jun 2023 | COVID-19 | Immune Biosolutions Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT05298813 | Sep 2021 → Jan 2023 | COVID-19 | Immune Biosolutions Inc | Completed | Missed primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT05639166 | Feb → May 2023 | COVID-19 | Immune Biosolutions Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-10-07 | Immune Biosolutions Inc | Results Safety and efficacy of inhaled IBIO123 for severe COVID-19, new results. immunebiosolutions.com ↗
Immune Biosolutions is pleased to share the most recent findings from our second Phase 1/2 clinical trial (NCT05303376). |
| 2023-08-21 | Immune Biosolutions Inc | Results Immune Biosolutions – A step closer to the first inhaled antibody treatment for COVID-19 immunebiosolutions.com ↗ |
| 2022-01-10 | Immune Biosolutions Inc | Results Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron immunebiosolutions.com ↗
Recent results have confirmed that this drug, IBIO123, is capable of neutralizing SARS-CoV-2 (COVID-19) and all its current variants of concern (VOCs) that have emerged throughout the pandemic, including the latest Omicron variant. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-10-07 | Immune Biosolutions Inc | Safety and efficacy of inhaled IBIO123 for severe COVID-19, new results. immunebiosolutions.com ↗ |
| 2023-08-21 | Immune Biosolutions Inc | Immune Biosolutions – A step closer to the first inhaled antibody treatment for COVID-19 immunebiosolutions.com ↗ |
| 2022-01-10 | Immune Biosolutions Inc | Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron immunebiosolutions.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBIO123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05639166 ↗ |
| Modality | Monoclonal antibody | “IBIO123 is a cocktail of three, fully human, neutralising monoclonal antibodies against SARS-CoV-2.” PMID 37619584 ↗ Aug 2023 |
| Route | Inhaled | “Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19” PMID 37619584 ↗ Aug 2023 |